Tardive Dyskinesia
Conditions
Brief summary
Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.
Interventions
None listed
Sponsors
Evidera
Neurocrine Biosciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient has a cumulative lifetime exposure to antipsychotic medication of three months or more * Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM-5 * Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre-defined 2-week period) * Patient is able to read and understand English * Patient is willing and able to comply with the study requirements
Exclusion criteria
* Patient is unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Customized clinician-reported outcomes | 12 months | Clinician evaluation of patient burden due to tardive dyskinesia symptoms |
| EuroQOL 5 Dimensions EQ-5D-5L) | 12 months | General, single index measure for describing and valuing health-related quality of life. |
| Customized caregiver-reported outcomes: | 12 months | Caregiver evaluation of perceived burden of symptoms on patients as well as the impact on the caregiver |
| Sheehan Disability Scale (SDS) | 12 months | Assessment of functional impairment and disability |
Countries
United States
Contacts
Primary ContactEvidera RE-Kinect Registry Team
Outcome results
None listed